Sanguine’s Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research

Sanguine Biosciences – a biotechnology company focusing on technology development, patient engagement and study recruitment – will use its proprietary mobile application and direct-to-patient platform, called Sangre, to help Pfizer Inc. find and recruit people diagnosed with Congenital Insensitivity to Pain (CIP) and their family members to participate in voluntary research, which will be used to help potentially identify DNA mutations and hopefully aid in informing the development of potential therapies for chronic pain.

Protagen Signs Collaboration with QIAGEN to Develop Novel Protein-Based Companion Diagnostics for Autoimmune Therapies

Protagen AG recently announced that it has entered into a long-term collaboration agreement with QIAGEN targeting the development of novel protein-based companion diagnostics for autoimmune disorders. Under the terms of the agreement, QIAGEN will gain access to the proprietary SeroTag® technology platform of Protagen, which enables the discovery and validation of novel protein-based marker panels. Such markers hold great promise for the development into companion diagnostics to guide treatment decisions in various autoimmune disorders. Financial details of the collaboration were not disclosed.

Quest Diagnostics Introduces BRCAvantage Plus, Providing New Choices in Genetic Breast Cancer Risk Testing

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, recently announced BRCAvantage Plus, the company’s first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA as well as BRCA genes. The new service is now available in all 50 states.

CompanionDx Launches NGS-based Cancer Assays Using GenomOncology’s GO Clinical Workbench

CompanionDx Reference Lab, LLC, a high-complexity CLIA-certified laboratory specializing in pharmacogenomics, cancer companion diagnostics and targeted next-generation sequencing (NGS), recently announced it is offering a series of NGS-based assays related to cancer. To enable efficient and compliant clinical reporting from NGS, CompanionDx chose to partner with GenomOncology, an Ohio-based genomics technology and services provider.

IBM Watson Group Invests in Pathway Genomics to Help Personalize Consumer Health

Cognitive apps are in market today and continue to change the way professionals and consumers make decisions. To help accelerate this transformation, the IBM Watson Group (NYSE: IBM) announced an investment in Pathway Genomics Corporation, a clinical laboratory that offers genetic testing services globally, to help deliver the first-ever cognitive consumer-facing app based on genetics from a user’s personal makeup.